We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

600588:SSEYonyou Network Technology Co. Ltd. Class A Analysis

Data as of 2026-07-22 - not real-time

CN¥9.63

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Yonyou’s share price of 9.63 CNY sits just above its 20‑day SMA (9.25) but remains below the 50‑day (10.10) and 200‑day (12.92) averages, underscoring a bearish medium‑term trend. The RSI at 51 is neutral, while the MACD line is marginally above its signal, giving a slightly bullish histogram hint. Trading volume is on the rise, yet the 30‑day volatility of 44% signals a highly turbulent price environment. A DCF‑derived fair value of roughly 6.0 CNY versus the current 9.6 CNY price points to a significant overvaluation. Forward PE stands at 43.8×, well above the industry average of 33.8×, reinforcing the valuation concern. Revenue grew 6% year‑on‑year, but operating margins are deeply negative (‑47%) and the company posted a loss per share of –0.41 CNY. Despite positive operating cash flow, total debt (4.09 bn CNY) exceeds cash reserves, yielding a debt‑to‑equity ratio of 48% and a negative ROE. No dividend is paid, eliminating income‑return expectations. The Fear & Greed Index at 90.98 reflects “Extreme Greed,” suggesting market enthusiasm may be outpacing fundamentals. Overall, technical signals are mixed, fundamentals remain weak, and valuation is stretched, warranting a cautious stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price above 20‑day SMA but below longer‑term averages
  • High short‑term volatility and extreme market greed
  • Overvaluation relative to DCF fair value

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Modest revenue growth with improving forward EPS
  • Persistent operating losses and high leverage
  • Valuation still above peers despite cash‑flow positivity

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Continued overvaluation versus intrinsic worth
  • Negative profitability metrics and debt burden
  • Lack of dividend and uncertain turnaround timeline

Key Metrics & Analysis

Financial Health

Revenue Growth5.90%
Profit Margin-14.85%
P/E Ratio43.8
ROE-15.28%
ROA-3.83%
Debt/Equity48.10
P/B Ratio4.8
Op. Cash FlowCN¥829.8M
Free Cash FlowCN¥1.3B
Industry P/E33.8

Technical Analysis

TrendBearish
RSI51.2
SupportCN¥8.73
ResistanceCN¥10.10
MA 20CN¥9.25
MA 50CN¥10.10
MA 200CN¥12.92
MACDBullish
VolumeIncreasing
Fear & Greed Index90.98

Valuation

Fair ValueCN¥6.02
GradeOvervalued
TypeValue

Risk Assessment

Beta0.41
Volatility44.34%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.